Haematologisch Onkologische Schwerpunktpraxis

At the Haematologisch Onkologische Schwerpunktpraxis in Würzburg, investigators are exploring new approaches for patients with metastatic colorectal cancer. The focus is on improving long‑term outcomes by testing innovative adjuvant therapy strategies after surgery or ablation.

• Evaluation of active post‑resection chemotherapy versus observation
• Integration of molecular markers to guide treatment intensity
• Assessment of quality‑of‑life endpoints in advanced disease

These studies contribute to the site’s portfolio of 14 active trials and reflect collaboration among five dedicated investigators.

The clinic conducts a broad program targeting hematologic malignancies, including chronic lymphocytic leukemia, Waldenström’s Macroglobulinemia, multiple myeloma, and follicular lymphoma. Trials aim to test novel targeted agents, combination immunotherapies, and individualized treatment durations to enhance progression‑free survival and overall health in both treatment‑naïve and relapsed patients.

• BTK inhibitor‑based regimens combined with anti‑CD20 antibodies
• MRD‑guided therapy adaptation versus fixed‑duration protocols
• Frail‑patient focused studies evaluating tolerability in older adults

Through these efforts, the site advances personalized care for blood‑cancer patients while maintaining a strong research presence.

In addition to hematologic cancers, the practice evaluates solid‑tumor neoplasms such as early breast cancer. Current work investigates whether adding a CDK4/6 inhibitor to standard endocrine therapy can increase invasive disease‑free survival for patients with HR+/HER2‑ disease. The goal is to refine adjuvant treatment plans based on genomic and clinical risk factors.

• Comparison of CDK4/6‑targeted therapy plus endocrine treatment versus endocrine alone
• Use of dynamic biomarkers to personalize adjuvant regimens
• Monitoring of patient‑reported outcomes during therapy

This research complements the site’s broader oncology agenda and strengthens its role in multidisciplinary cancer care.